Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Brown on Germline and Somatic Testing in Ovarian Cancer

April 2nd 2020

Jubilee Brown, MD, discusses germline and somatic testing in ovarian cancer.

Investigators Seek to Improve SOC in Cervical Cancer

April 1st 2020

Motivated to move the needle in cervical cancer, investigators are adding durvalumab to standard-of-care concurrent chemoradiation therapy and brachytherapy to determine whether PD-L1 blockade is a key to improving survival outcomes.

Dr. Moore on Safety Profile of Mirvetuximab Soravtansine in Ovarian Cancer

March 27th 2020

Kathleen Moore, MD, discusses the safety profile of mirvetuximab soravtansine, an antibody-drug conjugate that targets the FRα transmembrane protein, in ovarian cancer.

VB-111 Hits Milestone in Phase III Platinum-Resistant Ovarian Cancer Trial

March 27th 2020

An independent panel determined that the investigational agent VB-111 met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without modification.

Racial Disparities Reported With Quality of Care in Endometrial Cancer

March 26th 2020

Jason D. Wright, MD, discusses the findings of this trial and how practice can shift to decrease the gap between African-American and white patients with endometrial cancer.

Dr. Mirza on the ENGOT-OV42-NSGO/AVANOVA-Triplet Trial in Recurrent Ovarian Cancer

March 25th 2020

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the planned phase III ENGOT-OV42-NSGO/AVANOVA trial in platinum-sensitive, recurrent ovarian cancer.

Dr. Dizon on Potential Challenges for Patients With Gynecologic Cancers

March 19th 2020

Don S. Dizon, MD, FACP, FASCO, discusses potential challenges for patients with gynecologic cancers.

AXL Kinase Becomes a Therapeutic Target in Its Own Right

March 17th 2020

Despite being implicated across the spectrum of cancer hallmarks, aberrant AXL signaling is just starting to emerge as a distinct anticancer target, with a growing focus on specific inhibitors as well as alternative novel drug designs.

Niraparib Takes Step Toward Chinese Approval for Frontline Maintenance in Ovarian Cancer

March 16th 2020

The China National Medical Products Administration has accepted a supplemental New Drug Application for niraparib for use as a frontline maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

Dr. Ledermann on the Additive Effects of Olaparib and Bevacizumab in Ovarian Cancer

March 14th 2020

Jonathan A. Ledermann, BSc, MD, FRCP, discusses the additive effects of olaparib (Lynparza) and bevacizumab (Avastin) in advanced ovarian cancer.

Dr. Penson on Research With PARP Inhibitors in Ovarian Cancer

March 14th 2020

Richard T. Penson, MD, MRCP, discusses unexpected findings from the phase III SOLO3 trial and ongoing research with PARP inhibitors in ovarian cancer.

Expert Encourages Use of Sentinel Lymph Node Staging in Endometrial Cancer

March 13th 2020

Carrie L. Langstraat, MD, discusses the role of sentinel lymph node biopsy in endometrial cancer.

NUC-1031 Shows Early Promise in Heavily Pretreated Platinum-Resistant Ovarian Cancer

March 13th 2020

The first-in-class nucleotide analogue NUC-1031 has demonstrated early clinical activity in heavily pretreated patients with platinum-resistant ovarian cancer.

Dr. Secord on Frontline Maintenance Therapy in Ovarian Cancer

March 13th 2020

Angeles Alvarez Secord, MD, discusses key takeaways from clinical trials that have evaluated frontline maintenance strategies in patients with advanced ovarian cancer.

FDA Grants Balstilimab/Zalifrelimab Dual Immunotherapy Fast Track Designation in Cervical Cancer

March 13th 2020

The FDA has granted a Fast Track designation to the combination of the PD-1 inhibitor balstilimab and the CTLA-inhibitor zalifrelimab for the treatment of patients with relapsed or refractory metastatic cervical cancer.

Cediranib/Olaparib Combo Falls Short in Phase III Relapsed Ovarian Cancer Trial

March 12th 2020

Cediranib plus olaparib did not lead to a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.

Dr. Gonzalez-Martin on the PRIMA Trial Design in Ovarian Cancer

March 12th 2020

Antonio González-Martín, MD, discusses the design of the PRIMA trial in ovarian cancer.

Maurie Markman, MD: Confronting the Complexities of Care in Gynecologic Cancers

March 11th 2020

In our exclusive interview, Dr. Markman shares the reasons why he dove into the gynecologic cancer space, what mottos he lives by in daily practice, and patient cases that have significantly impacted his career.

FDA Approves Cytology Test to Enhance Cervical Cancer Prevention

March 11th 2020

The FDA has approved the CINtec PLUS Cytology test as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus using the cobas 4800 HPV Test.

Dr. Coleman on the VELIA Trial Impact on Ovarian Cancer Practice

March 11th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the impact of the VELIA trial on ovarian cancer practice.